Querard, A
Im not going to place a $5,000 implant in someone whose body isnt capable of healing it properly
Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)
The medication remains active in the body for over a week, so occasional missed doses typically don't cause immediate significant effects [3]
It improves sports performance, raises nitric oxide levels in the blood, increases blood flow to muscle tissues, enhances pumps, and stimulates lean growth
Aging and kidney biology Likewise, Related ERR-agonist work has examined mitochondrial dysfunction, inflammation, fibrosis, and renal function in aging models
